MRDR at Blood 2023

The MRDR had a successful Blood 2023. We kicked things off with our Annual Breakfast Meeting, which was well attended with around 95 attendees representing hospitals, researchers, industry, Government and other collaborators. Attendees enjoyed an update on the Australia and New Zealand (ANZ) MRDR, as well as its sister registry, the Asia-Pacific (APAC) MRDR. In addition, attendees had the opportunity to learn about emerging projects using registry data. These were the: MY-PROMPT-2 Trial and EpiMAP disease modelling study. This was followed by a lively Q&A session.






Pictured: MRDR team and MRDR site representatives after the Annual Breakfast Meeting at Blood 2023. 

The MRDR was also well represented in the conference program with four poster presentations that showed the breadth of use of registry data:

  • More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient reported outcome measures. E Moore et al.
  • Factors associated with self-reported quality of life in a longitudinal study of patients with multiple myeloma (MM) in the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR). C Wellard et al
  • Modelling multiple myeloma using best clinical response to treatment to predict overall survival. A Irving et al
  • Inferior outcomes in t(11;14) multiple myeloma: a report from the Australian Lymphoma Leukaemia Group (ALLG) and the ANZ Myeloma and Related Diseases Registry (MRDR). K JC Lim et al.

    Thanks to patients, research staff and clinicians at MRDR sites for your contribution to this research!

Pictured: Dr Adam Irving, Dr Cameron Wellard, Dr Elham Ashrafi, and Dr Elizabeth Moore presenting their respective posters. 

The Registry was also represented in the Monash University booth in the conference Exhibition Hall at breaks to promote the MRDR and attend to any queries. It was lovely to meet new (and familiar) faces!